Listen

Press releases

Receive e-mail alerts

Internal link ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
August 11, 2022 at 11:00 AM UTC
Internal link ProQR Announces Second Quarter 2022 Operating and Financial Results
August 04, 2022 at 11:00 AM UTC
Internal link ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
June 28, 2022 at 11:00 AM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
June 01, 2022 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022
May 09, 2022 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2022 Operating and Financial Results
May 05, 2022 at 08:30 PM UTC
Internal link ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022
April 26, 2022 at 08:10 PM UTC
Internal link ProQR to Participate in the Kempen Life Sciences Conference
April 19, 2022 at 08:30 PM UTC
Internal link ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
April 13, 2022 at 11:00 AM UTC
Internal link ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit
April 04, 2022 at 11:00 AM UTC
Internal link ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit
March 23, 2022 at 08:30 PM UTC
Internal link ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board
March 07, 2022 at 12:00 PM UTC
Internal link ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
February 24, 2022 at 12:00 PM UTC
Internal link ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
February 11, 2022 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming SVB Leerink Conference
February 07, 2022 at 09:30 PM UTC
Internal link ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen
January 04, 2022 at 12:00 PM UTC
Internal link ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
December 30, 2021 at 12:00 PM UTC
Internal link ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
December 16, 2021 at 12:00 PM UTC
Internal link ProQR Announces Highlights from Analyst Event
November 18, 2021 at 09:01 PM UTC
Internal link ProQR to Webcast Virtual Analyst Event on November 18
November 11, 2021 at 12:00 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences in November and December
November 08, 2021 at 09:30 PM UTC
Internal link ProQR Announces Third Quarter 2021 Operating and Financial Results
November 04, 2021 at 11:00 AM UTC
Internal link ProQR Appoints Theresa Heggie as Chief Commercial Officer
October 04, 2021 at 12:00 PM UTC
Internal link ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform
September 08, 2021 at 08:15 PM UTC
Internal link ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
September 08, 2021 at 08:01 PM UTC

Press releases

Internal link ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

Internal link ProQR Announces Second Quarter 2022 Operating and Financial Results

Internal link ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium

Internal link ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

Internal link ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022

Internal link ProQR Announces First Quarter 2022 Operating and Financial Results

Internal link ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022

Internal link ProQR to Participate in the Kempen Life Sciences Conference

Internal link ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy

Internal link ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit

Internal link ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit

Internal link ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board

Internal link ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

Internal link ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10

Internal link ProQR to Present at Upcoming SVB Leerink Conference

Internal link ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen

Internal link ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital

Internal link ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa

Internal link ProQR Announces Highlights from Analyst Event

Internal link ProQR to Webcast Virtual Analyst Event on November 18

Internal link ProQR Announces Upcoming Investor Conferences in November and December

Internal link ProQR Announces Third Quarter 2021 Operating and Financial Results

Internal link ProQR Appoints Theresa Heggie as Chief Commercial Officer

Internal link ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform

Internal link ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly